Lin Qianyi, Zhang Ming, Kong Ying, Huang Ziyuan, Zou Zhuoheng, Xiong Zhuolong, Xie Xiaolin, Cao Zitong, Situ Wanyi, Dong Jiaxin, Li Shufang, Zhu Xiao, Huang Yongmei
The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524023, China.
Department of Physical Medicine and Rehabilitation, Zibo Central Hospital, Zibo 255000, China.
Heliyon. 2023 Feb 17;9(3):e13811. doi: 10.1016/j.heliyon.2023.e13811. eCollection 2023 Mar.
Doxorubicin is the most effective anthracycline chemotherapy drug in the treatment of cancer, and it is an effective single agent in the treatment of non-small cell lung cancer (NSCLC). There is a lack of studies on the differentially expressed doxorubicin metabolism-related lncRNAs in NSCLC. In this study, we extracted related genes from the TCGA database and matched them with lncRNAs. Doxorubicin metabolism-related lncRNA-based gene signatures (DMLncSig) were gradually screened from univariate regression, LASSO regression, and multivariate regression analysis, and the risk score model was constructed. These DMLncSig were subjected to a GO/KEGG analysis. We then used the risk model to construct the TME model and analyze drug sensitivity. The IMvigor 210 immunotherapy model was cited for validation. Eventually, we performed tumor stemness index differences, survival, and clinical correlation analyses.
多柔比星是治疗癌症最有效的蒽环类化疗药物，是治疗非小细胞肺癌（NSCLC）的有效单药。目前缺乏关于NSCLC中多柔比星代谢相关长链非编码RNA（lncRNA）差异表达的研究。在本研究中，我们从TCGA数据库中提取相关基因并与lncRNA进行匹配。通过单变量回归、LASSO回归和多变量回归分析逐步筛选出基于多柔比星代谢相关lncRNA的基因特征（DMLncSig），并构建风险评分模型。对这些DMLncSig进行GO/KEGG分析。然后我们使用风险模型构建肿瘤微环境（TME）模型并分析药物敏感性。引用IMvigor 210免疫治疗模型进行验证。最终，我们进行了肿瘤干性指数差异、生存和临床相关性分析。
